JP2019518026A5 - - Google Patents

Info

Publication number
JP2019518026A5
JP2019518026A5 JP2018563619A JP2018563619A JP2019518026A5 JP 2019518026 A5 JP2019518026 A5 JP 2019518026A5 JP 2018563619 A JP2018563619 A JP 2018563619A JP 2018563619 A JP2018563619 A JP 2018563619A JP 2019518026 A5 JP2019518026 A5 JP 2019518026A5
Authority
JP
Japan
Prior art keywords
compound
formula
crystal
crystals
solvate
Prior art date
Application number
JP2018563619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518026A (ja
JP7054528B2 (ja
JPWO2017206924A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/086760 external-priority patent/WO2017206924A1/zh
Publication of JP2019518026A publication Critical patent/JP2019518026A/ja
Publication of JPWO2017206924A5 publication Critical patent/JPWO2017206924A5/ja
Publication of JP2019518026A5 publication Critical patent/JP2019518026A5/ja
Application granted granted Critical
Publication of JP7054528B2 publication Critical patent/JP7054528B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018563619A 2016-06-01 2017-06-01 プロテインキナーゼ活性を抑制する化合物の結晶形態、及びその適用 Active JP7054528B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/084300 2016-06-01
CNPCT/CN2016/084300 2016-06-01
PCT/CN2017/086760 WO2017206924A1 (zh) 2016-06-01 2017-06-01 抑制蛋白激酶活性化合物的晶型及其应用

Publications (4)

Publication Number Publication Date
JP2019518026A JP2019518026A (ja) 2019-06-27
JPWO2017206924A5 JPWO2017206924A5 (https=) 2022-03-15
JP2019518026A5 true JP2019518026A5 (https=) 2022-03-15
JP7054528B2 JP7054528B2 (ja) 2022-04-14

Family

ID=60477983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018563619A Active JP7054528B2 (ja) 2016-06-01 2017-06-01 プロテインキナーゼ活性を抑制する化合物の結晶形態、及びその適用

Country Status (17)

Country Link
US (1) US10899744B2 (https=)
EP (1) EP3470410B1 (https=)
JP (1) JP7054528B2 (https=)
KR (1) KR102466958B1 (https=)
CN (1) CN109195964B (https=)
AU (1) AU2017274110B2 (https=)
CA (1) CA3026142C (https=)
EA (1) EA201892687A1 (https=)
ES (1) ES2981015T3 (https=)
IL (1) IL263356B (https=)
MY (1) MY188379A (https=)
PH (1) PH12018502529A1 (https=)
PL (1) PL3470410T3 (https=)
RU (1) RU2744264C2 (https=)
SG (1) SG11201810800VA (https=)
TW (1) TWI646094B (https=)
WO (1) WO2017206924A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279579B2 (en) 2018-06-21 2023-02-01 Betta Pharmaceuticals Co Ltd Crystalline form of a compound to inhibit the activity of cdk4/6 and its use
EP4188922A1 (en) 2020-08-03 2023-06-07 Teva Pharmaceuticals International GmbH Solid state forms of ensartinib and ensartinib salts
EP4385510A4 (en) * 2021-08-10 2025-08-20 Betta Pharmaceuticals Co Ltd USE OF ENSARTINIB OR A CORRESPONDING SALT IN THE TREATMENT OF A DISEASE CARRYING A MET EXON 14 SKIPPING MUTATION
KR102851417B1 (ko) * 2022-08-16 2025-08-28 제이투에이치바이오텍 (주) 피리미딘-4-카복사마이드 화합물의 결정형 및 이를 포함하는 경구용 약학 제제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL358271A1 (pl) * 2000-03-06 2004-08-09 Warner-Lambert Company 5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny
CA2517256C (en) * 2003-02-26 2013-04-30 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
US8414489B2 (en) 2003-11-13 2013-04-09 Medtronic Minimed, Inc. Fabrication of multi-sensor arrays
ME01309B (me) * 2004-08-26 2013-12-20 Pfizer Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza
BRPI0514687A (pt) 2004-08-26 2008-06-17 Pfizer compostos amino heteroarila como inibidores de proteìna tirosina cinase
KR101146852B1 (ko) * 2005-12-05 2012-05-16 화이자 프로덕츠 인크. C?met/hgfr 억제제의 다형체
CN101652068A (zh) * 2007-01-19 2010-02-17 艾科睿制药公司 激酶抑制物化合物
ES2670665T3 (es) * 2008-06-19 2018-05-31 Xcovery Holding Company Llc Compuestos de piridazina carboxamida sustituidos como compuestos inhibidores de quinasa
EA024809B1 (ru) * 2010-10-08 2016-10-31 Икскавери Холдинг Кампани, Ллс Замещенные соединения пиридазинкарбоксамида
WO2012048258A2 (en) * 2010-10-08 2012-04-12 Xcovery Holding Company, Llc Substituted pyridazine carboxamide compounds as kinase inhibitor compounds

Similar Documents

Publication Publication Date Title
CN102510855B (zh) N-[3-氟-4-({6-(甲基氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n′-(4-氟苯基)环丙烷-1,1-二甲酰胺的晶形
TW201617347A (zh) 一種jak激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法
JP2019518026A5 (https=)
JP2018520178A (ja) プリナブリン組成物
CN111164085B (zh) 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
WO2018184185A1 (zh) 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
CN105324375A (zh) 盐酸尼洛替尼的多晶型形式
WO2015139591A1 (zh) 德罗格韦钠盐的晶型及其制备方法
CN104098570A (zh) 替卡格雷晶型及其制备方法和用途
JP2019531323A (ja) (r)−4−ヒドロキシ−2−オキソ−1−ピロリジンアセトアミドの結晶型、調製方法、用途
RU2018145183A (ru) Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение
WO2018103027A1 (zh) 替吡法尼的晶型及其制备方法及药物组合物
CN111247153B (zh) 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1,3]间二氧杂环戊烯并[4,5-f]吲哚-7-基)吡咯-2,5-二酮的固体形式
CN114685431B (zh) 一种阿昔替尼柠檬酸盐晶型
WO2019195569A1 (en) Solid-state forms of abemaciclib, their use and preparation
JPWO2017206924A5 (https=)
WO2003045953A1 (en) Crystals of taxane derivative and process for their production
CN116120341A (zh) Gdc-0077的晶型及其制备方法和用途
TW201734023A (zh) 溫諾平(vinorelbine)單酒石酸鹽及其藥學用途
US7777049B2 (en) Crystalline forms of Rizatriptan benzoate
JP2018510173A (ja) トピロキソスタットの新規結晶形及びその製造方法
CN105294808B (zh) 醋酸乌利司他晶g型物质及制备方法和其组合物与用途
WO2023202651A1 (en) Polymorphic forms of glutamine antagonist and uses thereof
EP3710425A1 (en) Solid state forms of elafibranor
CN113943270B (zh) 一种阿昔替尼晶型